Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $171,655 - $228,492
4,964 New
4,964 $202,000
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $126,709 - $250,883
-3,292 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $5,360 - $10,947
92 Added 2.88%
3,292 $239,000
Q4 2021

Feb 14, 2022

BUY
$100.76 - $138.36 $49,876 - $68,488
495 Added 18.3%
3,200 $378,000
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $503,403 - $672,294
-3,803 Reduced 58.44%
2,705 $363,000
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $22,221 - $59,097
-365 Reduced 5.31%
6,508 $1.05 Million
Q1 2021

May 18, 2021

SELL
$46.59 - $83.68 $356,786 - $640,821
-7,658 Reduced 52.7%
6,873 $552,000
Q4 2020

Feb 17, 2021

SELL
$18.83 - $63.53 $9,302 - $31,383
-494 Reduced 3.29%
14,531 $790,000
Q3 2020

Nov 19, 2020

BUY
$17.47 - $24.93 $80,711 - $115,176
4,620 Added 44.4%
15,025 $299,000
Q2 2020

Aug 14, 2020

SELL
$11.14 - $22.87 $23,394 - $48,027
-2,100 Reduced 16.79%
10,405 $219,000
Q1 2020

May 13, 2020

BUY
$9.44 - $15.58 $118,047 - $194,827
12,505 New
12,505 $153,000
Q2 2019

Aug 12, 2019

SELL
$13.88 - $18.41 $146,211 - $193,930
-10,534 Closed
0 $0
Q1 2019

May 16, 2019

BUY
$12.79 - $17.62 $2,711 - $3,735
212 Added 2.05%
10,534 $180,000
Q4 2018

Feb 15, 2019

BUY
$11.39 - $27.13 $25,969 - $61,856
2,280 Added 28.35%
10,322 $141,000
Q3 2018

Nov 14, 2018

SELL
$25.78 - $32.6 $5,156 - $6,520
-200 Reduced 2.43%
8,042 $230,000
Q1 2018

May 15, 2018

BUY
$19.43 - $34.95 $3,886 - $6,990
200 Added 2.49%
8,242 $170,000
Q3 2017

Nov 14, 2017

BUY
$15.16 - $25.75 $121,916 - $207,081
8,042
8,042 $234,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $707M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Iht Wealth Management, LLC Portfolio

Follow Iht Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Iht Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Iht Wealth Management, LLC with notifications on news.